Sold as Naquival, Metatensin #2, Metatensin #4. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 15, 2026, FDA lists 3 applications for Reserpine; Trichlormethiazide (sold as Naquival, Metatensin #2, Metatensin #4), first approved Mar 9, 1960, with 0 new uses approved and 0 published complete response letters.
| Mar 9, 1960 | Naqua, NaquivalNDA 12265 · New molecular entity | Schering | 0 | Discontinued |
| — | Trichlormethiazide W/ ReserpineANDA 85248 | Watson Labs | 2 | Discontinued |
| — | Metatensin #2, Metatensin #4NDA 12972 | Sanofi Aventis US | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Schering
Sanofi Aventis US